Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02823821 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Randomised Evaluation of Sodium Dialysate Levels on Vascular Events

Study acronym: RESOLVE
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Dec 2024 to Dec 2026v38
  2. Study sites: 187 to 264v37
  3. Study sites: 166 to 187v36
  4. Study sites: 117 to 166
    • Collaborators: 10 to 11
    v35
  5. Collaborators revised (10)v34
Show 32 earlier versionsHide 32 earlier versions
  1. Lead sponsor: The George Institute to University of Sydneyv33 Show 5 more changesShow less
    • Primary and study completion dates: Dec 2023 to Dec 2024
    • Enrollment target: 51520 to 50000
    • Study sites: 142 to 117
    • Study description shortened, about 42 words
    • Collaborators: 1 to 10
  2. Study sites: 134 to 142v32
  3. Study sites: 133 to 134v31
  4. Study sites: 131 to 133v30
  5. Study sites: 130 to 131v29
  6. Study sites: 129 to 130v28
  7. Study sites: 128 to 129v27
  8. Study sites: 123 to 128v26
  9. Study sites: 122 to 123v25
  10. Study sites: 121 to 122v24
  11. Study sites: 115 to 121v23
  12. Study sites: 114 to 115v22
  13. Study sites: 111 to 114v21
  14. Study sites: 97 to 111v20
  15. Study sites: 96 to 97v19
  16. Study sites: 90 to 96v18
  17. Study sites: 88 to 90v17
  18. Study sites: 75 to 88v16
  19. Study sites: 64 to 75v15
  20. Study sites: 55 to 64v14
  21. Study sites: 51 to 55v13
  22. Study sites: 49 to 51v12
  23. Study sites: 43 to 49v11
  24. Study sites: 42 to 43v10
  25. Study sites: 41 to 42v9
  26. Study sites: 39 to 41v8
  27. Study sites: 38 to 39v7
  28. Study sites: 31 to 38v6
  29. Study sites: 18 to 31v5
  30. Study sites: 2 to 18v4
  31. Secondary endpoints: details revised at 2 of 2 entriesv3
  32. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 2 of 2 sites
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This global study will assess the effect of randomising dialysis sites to one of two default dialysate sodium concentrations in current practice, 140mmol/l and 137mmol/l, on major cardiovascular events and death in patients receiving maintenance haemodialysis.
Trial Details
NCT Number NCT02823821
Lead Sponsor University of Sydney
Collaborators: Australasian Kidney Trials Network, Australia & New Zealand Dialysis & Transplant Registry, The George Institute, The George Institute for Global Health, China, Peking University People's Hospital, Institute for Clinical Evaluative Sciences, St. Michaels Hospital, Wuerzburg University Hospital, Malaysian Society of Nephrology, Malaysian Renal Registry, University College, London
Conditions
(from sponsor)		 End-Stage Kidney Disease
Related terms Kidney Failure, Chronic
Enrollment 50,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov